|
New Delhi: In what promises to protect people against the world’s most widespread form of malaria, a candidate vaccine developed by Indian researchers at the New Delhi-based International Centre for Genetic Engineering and Biotechnology (ICGEB) is all set to undergo human clinical trials in the middle of this year.
ICGEB has entered into an agreement with Hyderabad-based biotech firm Bharat Biotech Ltd, which would manufacture the vaccine for human clinical trials later this year. The researchers at ICGEB have fine-tuned the candidate vaccine against infection from Plasmodium vivax, the most widespread form of malaria in India, and transferred the technology to Bharat Biotech.
“The Indian malaria vaccine programme now ranks amongst the best in the world and has attracted funds for the production of vaccine grade materials involving the biotechnology industry in India, clearing the way for the first-ever malaria vaccine trials in India,” ICGEB director Prof VS Chauhan told eFE.
ICGEB, with laboratories in New Delhi and Trieste, Italy, is dedicated to developing and promoting application of biotechnology for solving problems in health and agriculture, particularly in developing countries.
 |
| VS Chauhan |
According to Ernst & Young (E&Y) India head of health sciences practice Utkarsh Palnitkar, “It is a sign not only of a successful partnership between...
More from Front Page
| Single Page Format | 1 - 2 - Next |
Discuss this story on expressindia forums
|
|
 |
 |
 |
About Us | Contact Us | Advertisers | Site Map | Make us your homepage | Work for Us | RSS | Subscribe | Electronic Edition | Privacy Policy© 2010: The Indian Express Limited. All rights reserved throughout the world
